Cancer
Researchers modify T-cells to identify and target multiple sites on leukaemia cells
April 1, 2020Research and Development Cancer, Cancers, children cancer, leukaemia
Scientists from the Children’s Hospital of Los Angeles have engineered T-cells to identify and target multiple sites on acute lymphoblastic …
Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer
March 31, 2020Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer
The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …
FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer
March 30, 2020Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma
AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …
Roche shows improved survival rates in new treatment for untreated acute myeloid leukaemia
March 24, 2020Manufacturing and Production Cancer, Roche, acute myeloid leukamia
Roche has announced that its clinical trials for Venclexta/Venclyzto combination with azacitidine have met its primary endpoints of overall survival …
AI may help predict patient response to non-small cell lung cancer therapies
March 23, 2020Medical Communications, Sales and Marketing Cancer, Lesions, cancer treatment, tumour treatment
Researchers have used artificial intelligence to train algorithms to predict tumour sensitivity to systemic cancer therapies. Radiologists previously determined if …
New findings on influenza could help improve cancer treatments
March 20, 2020Manufacturing and Production, Medical Communications Cancer, cancer treatments, flu, flu treatments, influenza
A new study into how the body fights influenza could help improve cancer immunotherapies. Researchers at the Fox Chase Cancer …
Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer
March 17, 2020Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma
AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …
Bavencio Phase 3 head and neck cancer trial terminated
March 16, 2020Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure
Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …
Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
March 12, 2020Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …
Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows
March 6, 2020Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma
Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …
Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma
Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …
E. coli strain in the gut may increase risk of bowel cancer, new study finds
February 28, 2020Medical Communications Cancer, E. coli, bowel cancer, bowels, cancer research, e coli, oncology
A type of E. coli infection may increase a person’s chance of developing bowel cancer, according to a new study …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
February 27, 2020Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …
Latest content
Five Facts about cardiovascular disease
